Dr. Brooke E. Daniel, MD

Dr. Daniel practices at Erlanger Baroness Hospital in Chattanooga, Tennessee, part of Erlanger Health.

Dr. Daniel's NPI, 1326096231, was assigned on May 4, 2006. Dr. Daniel graduated from University of Tennessee, Hsc, College of Medicine in 1998. Dr. Daniel holds Tennessee license MD39893.

Dr. Daniel's primary practice is Erlanger Baroness Hospital, at 975 E 3rd St, Chattanooga, TN 37403 in Hamilton County. The practice phone is (423) 778-7000.

Dr. Daniel's primary practice is Erlanger Baroness Hospital in Chattanooga, Tennessee, part of Erlanger Health. Dr. Daniel is also affiliated with CommonSpirit - Memorial Hospital - Chattanooga. The medical group on file is Tennessee Oncology. Dmand AI also links Dr. Daniel to 1 more hospital, 2 group practices and clinics, 1 community health center and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Daniel practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Daniel's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Daniel's licenses on file in 2 states: Tennessee and Georgia.

CMS data shows 45,889 Medicare services from Dr. Daniel across 56 procedure codes in 2024, for 794 Medicare patients. Medicare paid $296,679 for them.

CMS counts 794 Medicare patients who saw Dr. Daniel in 2024. The largest group is 65 to 74, with 378 patients. 75% of them have high blood pressure, and 71% have cancer. 8% are also on Medicaid. Their average risk score is 1.83, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Daniel's median patient age at 67, with 78% women.

In 2024, Dr. Daniel wrote 1,448 Medicare Part D claims for 318 patients. 79% of them were for generic drugs. CMS names the drug for 1,119 of them, across 34 drugs with 11 or more claims each, at $3,111,848 in total drug cost. In 2023, CMS named 1,207 claims across 36 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Daniel for performance year 2024, reported as part of a group. Dr. Daniel accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 10 papers to Dr. Daniel, published from 2013 to 2023. 2016 was the busiest year, with 2. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms and Receptor, ErbB-2. Dr. Daniel has published most often in Breast Cancer Res Treat. Dr. Daniel's most frequent co-authors are John D. Hainsworth, MD, Robyn R. Young, MD and Howard A. Burris, MD.

Dmand AI links Dr. Daniel to 10 clinical trials, 4 of them phase 2 studies. 5 are still active or recruiting. Conditions studied include Breast Neoplasms, Neoplasm Metastasis and Breast Diseases. Eli Lilly and Company sponsors the most, 3. Open Payments lists research payments to Dr. Daniel that name 3 trials.

CMS Open Payments shows 87 general payments to Dr. Daniel from 28 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 96% of the total. Tactile Systems Technology Inc paid the most, $338. It also lists 6 research payments totaling $9,835 from 2016 to 2025, naming 3 clinical trials.

Dr. Daniel graduated from University of Tennessee, Hsc, College of Medicine in 1998.